These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 24887559)

  • 1. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
    Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H
    Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
    Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alectinib for treatment of ALK-positive non-small-cell lung cancer.
    Avrillon V; Pérol M
    Future Oncol; 2017 Feb; 13(4):321-335. PubMed ID: 27780368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
    Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K
    Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
    Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT
    Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
    Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
    Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
    Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
    Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
    Wong KM; Noonan S; O'Bryant C; Jimeno A
    Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
    Lin YT; Yu CJ; Yang JC; Shih JY
    Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
    Ou SH; Milliken JC; Azada MC; Miller VA; Ali SM; Klempner SJ
    Lung Cancer; 2016 Jan; 91():70-2. PubMed ID: 26464158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
    Sakamoto H; Tsukaguchi T; Hiroshima S; Kodama T; Kobayashi T; Fukami TA; Oikawa N; Tsukuda T; Ishii N; Aoki Y
    Cancer Cell; 2011 May; 19(5):679-90. PubMed ID: 21575866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
    Ge FJ; Dai XY; Qiu Y; Liu XN; Zeng CM; Xu XY; Chen YD; Zhu H; He QJ; Gai RH; Ma SL; Chen XQ; Yang B
    Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
    Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.